Dexmedetomidine provides neuroprotection: Impact on ketamine-induced neuroapoptosis in the developing rat brain

Acta Anaesthesiologica Scandinavica

Volumn 58, Issue 9, 2014, Pages 1121-1126

  Duan, X ^a   Li, Y ^b   Zhou, C ^a   Huang, L ^a   Dong, Zhenming ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Shijiazhuang First Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMEDETOMIDINE; KETAMINE; SODIUM CHLORIDE; ANALGESIC AGENT; ANESTHETIC AGENT; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR CHANGE; BRAIN DEVELOPMENT; BRAIN FUNCTION; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; HIPPOCAMPAL CA1 REGION; LATENT PERIOD; MALE; MEMORY; MORRIS WATER MAZE TEST; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NICK END LABELING; NONHUMAN; RAT; SPATIAL LEARNING; SWIMMING; TREATMENT DURATION; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; MAZE TEST; SPRAGUE DAWLEY RAT;

ANALGESICS, NON-NARCOTIC; ANALYSIS OF VARIANCE; ANESTHETICS, DISSOCIATIVE; ANIMALS; APOPTOSIS; BRAIN; DEXMEDETOMIDINE; DISEASE MODELS, ANIMAL; FEMALE; KETAMINE; MALE; MAZE LEARNING; MEMORY; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE;

EID: 84908229308     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12356     Document Type: Article

References (21)

1. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999; 283: 70-4
2. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M. Dexmedetomidine produces its neuroprotective effect via the a2A-adrenoceptor subtype. Eur J Pharmacol 2004; 502: 87-97
3. Cosar M, Eser O, Fidan H, Sahin O, Buyukbas S, Ela Y, Yagmurca M, Ozen OA. The neuroprotective effect of dexmedetomidine in the hippocampus of rabbits after subarachnoid hemorrhage. Surg Neurol 2009; 71: 54-9
4. Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, Sun P, Hossain M, Ma D, Maze M. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 2009; 110: 1077-85
5. Levänen J, Mäkelä ML, Scheinin H. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology 1995; 82: 1117-25
6. Selmi AL, Mendes GM, Figueiredo JP, Barbudo-Selmi GR, Lins BT. Comparison of medetomidine-ketamine and dexmedetomidine-ketamine anesthesia in golden-headed lion tamarins. Can Vet J 2004; 45: 481-5
7. Pontén E, Viberg H, Gordh T, Eriksson P, Fredriksson A. Clonidine abolishes the adverse effects on apoptosis and behaviour after neonatal ketamine exposure in mice. Acta Anaesthesiol Scand 2012; 56: 1058-65
8. Haberny KA, Paule MG, Scallet AC, Sistare FD, Lester DS, Hanig JP, Slikker W Jr. Ontogeny of the N-methyl-Daspartate (NMDA) receptor system and susceptibility of neurotoxicity. Toxicol Sci 2002; 68: 9-17
9. Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. Anesth Analg 2007; 104: 509-20
10. Canpolat DG, Esmaoglu A, Tosun Z, Akn A, Boyaci A, Coruh A. Ketamine-propofol vs. ketamine-dexmedetomidine combinations in pediatric patients undergoing burn dressing changes. J Burn Care Res 2012; 33: 718-22
11. Goyal R, Singh S, Shukla RN, Patra AK, Bhargava DV. Ketodex, a combination of dexmedetomidine and ketamine for upper gastrointestinal endoscopy in children: A preliminary report. J Anesth 2013; 27: 461-3
12. Huang L, Liu Y, Jin W, Ji X, Dong Z. Ketamine potentiates hippocampal neurodegeneration and persistent learning and memory impairment through the PKC?-ERK signaling pathway in the developing brain. Brain Res 2012; 1476: 164-71
13. Scallet AC, Schmued LC, Slikker W Jr., Grunberg N, Faustino PJ, Davis H, Lester D, Pine PS, Sistare F, Hanig JP. Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol Sci 2004; 81: 364-70
14. Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 2003; 23: 876-82
15. Jolkkonen J, Puurunen K, Koistinaho J, Kauppinen R, Haapalinna A, Nieminen L, Sivenius J. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol 1999; 372: 31-6
16. Kuhmonen J, Pokorný J, Miettinen R, Haapalinna A, Jolkkonen J, Riekkinen P Sr., Sivenius J. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 1997; 87: 371-7
17. Sanders RD, Maze M. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs 2007; 8: 25-33
18. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P, Gressens P. Effects of a2-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anesthesiology 2002; 96: 134-41
19. Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 2006; 102: 456-61
20. Linker R, Gold R, Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol 2009; 29: 43-68
21. Sanders RD, Sun P, Patel S, Li M, Maze M, Ma D. Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand 2010; 54: 710-6